Overview

The objective of this activity is to provide evidence-based information on the latest developments for the use of Bruton’s tyrosine kinase (BTK) inhibitors in patients with chronic lymphocytic leukemia (CLL). Given the demonstrated clinical benefit of BTKi therapy and its advantages over chemotherapy, it is essential for patients that the adoption of BTKi therapy continues to accelerate. Optimizing patient adherence to oral BTKis is vital to achieving efficacy and improving clinical outcomes. Hematology/oncology nurses must develop best practices for educating patients and monitoring adherence for those receiving oral BTKi therapy. Complicating the adherence landscape is the predominance of older patients with CLL, who are often on multiple medications and more complex regimens. As front-line caregivers, oncology nurses are optimally positioned to guide patients through therapy and properly manage adverse events that may arise with this therapy.

Speakers

Amy Goodrich, RN, MSN, CRNP-AC

Research Associate
The Johns Hopkins School of Medicine
Nurse Practitioner
The Sidney Kimmel Cancer Center at Johns Hopkins
Baltimore, Maryland
View Full Bio

Accreditation

CNE

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is designated for 1.00 contact hour.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Other

Creative Educational Concepts, Inc. certifies this activity for 1.00 hour of participation.

Acknowledgement

Supported by an independent educational grant from AstraZeneca.

Custom

CEC Oncology staff will provide secure login instructions upon scheduling your virtual chapter meeting.